Search PubMed⌕ Search

Biomedical subjects

Shomron Ben-Horin

Publications and source records attributed to Shomron Ben-Horin.

4 recordsLinked to original sources

Cholesterol crystal embolization to the digestive system: characterization of a common, yet overlooked presentation of atheroembolism.

In the 1359 published patients with multiorgan cholesterol crystal embolism (CCE), the digestive system seems to be the third most frequently affected system. Yet, this system received hitherto only little attention in the medical literature. Therefore, the aim of the present study was to clinically characterize the subset of patients with CCE involving the digestive system, based on our institutional experience and a review of the literature. Cases with CCE in a 7-yr period (1995-2001) were sought in the computerized records of our medical center. Of the CCE patients, those with digestive system involvement that could be related to CCE were included in this study. The clinical features of CCE were determined and compared with those found in published series. Fourteen cases with CCE were identified, giving an annual incidence of 0.8 per 10(5). Digestive system involvement was found in five (36%) of the 14 patients. All five patients had established atherosclerosis. Precipitating factors were vascular manipulations or anticoagulation treatment in four of these five patients. Two patterns of disease appeared: acute catastrophic multiorgan disorder with poor prognosis and chronic and more indolent GI disease. Abdominal pain, GI bleeding, fever, and diarrhea were the most common manifestations, resulting from bowel infarction, mucosal ulcerations, hepatocellular liver disorder, and/or pancreatitis. CCE is a systemic disorder with a frequent involvement of the digestive system and protean clinical manifestations. It should, therefore, be considered in any gastroenterological patient with atherosclerosis and recent vascular manipulations or systemic anticoagulation.

Aged↗

Gastroenteritis-associated hyperamylasemia: prevalence and clinical significance.

BACKGROUND: Serum amylase levels can be elevated in various pathological conditions. However, acute gastroenteritis has not been widely recognized as a cause for hyperamylasemia. PATIENTS AND METHODS: We conducted a retrospective study of amylase results for all patients hospitalized or discharged from the emergency department with a diagnosis of gastroenteritis from April through November 1999. Patients with other possible medical causes for elevated amylase levels were excluded. We also compared the clinical and laboratory parameters of hyperamylasemic vs. normoamylasemic hospitalized patients with gastroenteritis. RESULTS: A total of 1041 patients with acute gastroenteritis were identified. Serum amylase levels were determined in 701 patients and were abnormally elevated in 66 of them. In 15 patients, other possible causes of hyperamylasemia were present, and these patients were excluded. The mean serum amylase level among the remaining 51 patients (7.4% of the remaining 686 patients with gastroenteritis) was 1.32 of the upper normal level, with a range of up to 2.2 times the upper normal range. Clinicians tended to admit more hyperamylasemic patients than normoamylasemic patients (10 of 51 vs. 65 of 635; P =.03, 1 sided). However, the course of gastroenteritis in the hospitalized hyperamylasemic patients did not differ significantly from that in the hospitalized normoamylasemic patients, as judged by the clinical signs and symptoms, laboratory results, length of hospital stay, and need for antibiotics. CONCLUSIONS: Gastroenteritis is associated with a mild to moderate elevation of serum amylase levels in a significant portion of patients and should be included in the differential diagnosis of hyperamylasemia. Such elevation, however, does not seem to bear clinical significance in terms of the severity of disease.

Acute Disease↗

[Fever and chills following intravenous administration of NeyTumorin--an unconventional xenogenous derived peptides extract].

We report a 54 year old patient who was recently diagnosed with retroperitoneal recurrence of colon carcinoma, and who was admitted because of fever and chills. Extensive work-up yielded no source of infection, multiple blood cultures were sterile, and symptoms resolved within two days. During hospitalization, it was learned that her symptoms appeared an hour after a drug named NeyTumorin was administered to her intravenously by an alternative medicine practitioner. NeyTumorin is part of cell therapy, which is an alternative medicine therapy involving the administration of farm animals derived preparation of peptides from several organs, including the diencephalon and hypophysis. This case underscores the risk of invasive alternative medicine treatments, which are not subject to adequate scrutiny by the health authorities.

Antineoplastic Agents↗